Vizomitin(Vizomitin) - 在研适应症：干眼症_专利_临床

概要

基本信息

药物类型

小分子化药

别名-

靶点-

作用机制-

治疗领域

眼部疾病

在研适应症

干眼症

非在研适应症

家族遗传性视神经萎缩葡萄膜炎湿性年龄相关性黄斑变性

原研机构

Mitotech SA

在研机构

Mitotech SA

非在研机构

珠海亿胜生物制药有限公司亿胜生物制药有限公司

最高研发阶段批准上市

首次获批日期

俄罗斯 (2012-12-31),

干眼症

最高研发阶段(中国)无进展

特殊审评孤儿药 (美国)

登录后查看时间轴

结构

分子式C36H44O2P

InChIKeyWIIDCFZCTGOZCQ-UHFFFAOYSA-O

CAS号1147011-72-0

关联

100 项与 Vizomitin 相关的临床结果

登录后查看更多信息

100 项与 Vizomitin 相关的转化医学

登录后查看更多信息

100 项与 Vizomitin 相关的专利（医药）

登录后查看更多信息

1

项与 Vizomitin 相关的文献（医药）

2017-09-01·Anesteziologiia i reanimatologiia

[MITOCHONDRIA-TARGETED ANTIOXIDANTS IN THE PREVENTION OF THE CORNEA EROSION WHEN PERFORMING SURGERY UNDER GENERAL ANESTHESIA.]

Article

作者: Chemodanov, D V ; Gusev, E A ; Grebenchikov, O A ; Sungurov, V A ; Neverovsky, E A ; Likhvantsev, V V

Despite the use of modern methods of prevention, at least 10% of patients operated on for ophthalmic indications not develop corneal erosion as the indirect complication of general anesthesia.OBJECTIVETo reduce the number of ophthalmic complications of general anesthesia by prophylactic use of new mito- chondria-targeted antioxidants - Vizomitin (eye drops).MATERIALS AND METHODS70 patients, which was supposed to perform the average duration of operations under general anesthesia were randomized into 3 groups depending on the method specific (pharmacological) prevention of corneal erosions: (1) control (specic (pharmacological) prevention was not carried out), (2), using preparation "natural tear, and (3) "Vizomitin" preparation. Postoperative biomicroscopy was performed to assess the condition of the cornea, tear film stability was measured and the height of the tear meniscus.RESULTSWhen using eye drops "Vizomitin" value is an indicator of stability of the tear film on the 3rd day after the operation more than in the control group of patients by 51% (p = 0.012) and patients groups, natural tear by 57% (p = 0.013). Surgical interventions performed under general anesthesia, leading to an increase in the number ofpatients with decreased tear meniscus height index of the control group with 4 to 7 patients (p = 0.30) in the group of natural tear from 3 to 11 patients (p = 0.008) . In the group with drug "Vizomitin" the number of such patients is reduced from 7 to 1 (p = 0.018).CONCLUSIONIn the surgical procedures under general anesthesia eye drops "Vizomitin" effectively prevents the devel- opment of corneal erosion.

100 项与 Vizomitin 相关的药物交易

登录后查看更多信息

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
干眼症	俄罗斯	Mitotech SA	2012-12-31

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
湿性年龄相关性黄斑变性	临床2期	美国	Mitotech SA	2018-12-12
干眼症	临床2期	美国	亿胜生物制药有限公司	2018-10-22
干眼症	临床2期	美国	Mitotech SA	2018-10-22
葡萄膜炎	临床2期	卢森堡	Mitotech SA	2016-01-29
家族遗传性视神经萎缩	临床2期	俄罗斯	Mitotech SA	2013-10-26